24 May 2013
Keywords: first, phase, iii, data, roche/trimeris, hiv, drug
Article | 22 April 2002
T-20, the HIV fusion inhibitor in development at Roche and Trimeris, hasbeen shown in a Phase III study to offer ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 April 2002
© 2013 thepharmaletter.com